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a  b  s  t  r  a  c  t
The  US  Centers  for Disease  Control  & Prevention  currently  recommend  routine  immunization  to prevent
17  vaccine-preventable  diseases  that  occur  in  infants,  children,  adolescents,  or adults.  Pregnant  women
are  at  particularly  high  risk  for  morbidity  and  mortality  related  to several  vaccine-preventable  diseases.
Furthermore,  such  illnesses  are  also  associated  with  adverse  pregnancy  outcomes  such as  spontaneous
abortion,  congenital  anomalies,  preterm  birth,  and  low  birthweight.  In  addition  to  directly  preventing
maternal  infection,  vaccination  during  pregnancy  may  offer  fetal  and  infant  beneﬁt  through  passive
immunization.  Several  vaccines  aimed  at providing  passive  immunity  to  neonates  are  either  currently
recommended  or in development.  This  article  speciﬁcally  addresses  maternal  beneﬁts  of maternal  immu-
nization  following  (1)  vaccines  recommended  for all pregnant  women;  (2)  vaccines  recommended  for
pregnant  women  with  particular  risk  factors;  and  (3)  novel  vaccines  currently  under  development  that
primarily  aim to  at reduce  infant  morbidity  and  mortality.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Pregnancy is a particularly susceptible period for maternal and
nfant complications associated with vaccine preventable diseases
VPDs). Pregnant women are at high risk for inﬂuenza-related
orbidity and mortality, including higher rates of hospitalization,
ardiopulmonary complications, and death compared to the gen-
ral public [1]. Maternal inﬂuenza infection is associated with
dverse birth outcomes including preterm birth, fetal growth
estriction, and fetal demise [1]. Both maternal and fetal compli-
ations are further elevated during pandemic inﬂuenza seasons.
aternal–fetal transmission of varicella and rubella are associated
ith congenital malformations and life-long infection in the case of
epatitis B. Beyond preventing maternal and fetal infection, mater-
al immunization should provide infant protection through passive
mmunization, i.e. via transplacental transfer of maternal IgG anti-
odies as well as transfer of maternal IgA antibodies via breast
ilk [2,3]. The potential for passive immunization to protect youngnfants against pertussis infection has been the primary driver for
he recent recommendation for administration of tetanus, diphthe-
ia, acellular pertussis (Tdap) vaccination during each and every
∗ Corresponding author at: Duke University, 2608 Erwin Rd, Suite 210 Durham,
C  27705, United States. Tel.: +1 919 668 1600; fax: +1 919 613 1550.
E-mail address: geeta.swamy@duke.edu (G.K. Swamy).
ttp://dx.doi.org/10.1016/j.vaccine.2015.08.035
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
pregnancy [4]. In addition to the six vaccines (vaccines against
inﬂuenza, Tdap, pneumococcus, meningococcus, Hepatitis A and
B) that are currently recommended by the US Centers for Dis-
ease Control & Prevention (CDC) for use during pregnancy (with
some contingent upon risk factors), novel vaccines against group B
streptococcus and respiratory syncytial virus are currently being
evaluated for administration during pregnancy [5–7]. Although
novel vaccine candidates are focusing primarily on the potential
for infant disease prevention, this article speciﬁcally addresses
maternal beneﬁts of immunization during pregnancy following:
(1) vaccines recommended for all pregnant women; (2) vaccines
recommended for pregnant women  with particular risk factors;
and (3) vaccines primarily aimed at reducing infant morbidity and
mortality (Table 1).
2. Vaccines recommended for all pregnant Women
2.1. Inﬂuenza
Approximately 20% of the US population will have inﬂuenza dur-
ing a single non-pandemic season compared to nearly 50% during a
pandemic season [1]. Similarly, 20% of pregnant women will suffer
from an inﬂuenza-like illness (ILI) during a non-pandemic season,
with 10% having laboratory-conﬁrmed inﬂuenza [8]. Presumably
due to changes in immunology and cardiorespiratory physiology
rather than susceptibility to acquisition, pregnant and immediately
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table  1
Licensed and novel vaccines for pregnant women.
Vaccines recommended for all pregnant
women
Vaccines recommended for pregnant women with risk factors Novel vaccines aimed at reducing infant infection
through maternal immunization
Inactivated inﬂuenza vaccine (IIV) Pneumococcal polysaccharide 23-serotype vaccine (PPSV23) Trivalent group B streptococcus polysaccharide
vaccine
Tetanus, diphtheria, acellular pertussis (Tdap) Meninogococcal tetravalent polysaccharide vaccine (MPSV4) Inactivated respiratory syncytial virus vaccine






















































wRecombinant hepatitis B vaccin
ostpartum women are at high risk for inﬂuenza-related morbidity
nd mortality including hospitalization, cardiopulmonary compli-
ations, and death [9]. Beyond maternal complications, inﬂuenza
nfection in pregnancy is associated with adverse birth outcomes
ncluding spontaneous abortion, preterm birth, low birthweight,
nd fetal demise [1]. Both maternal and fetal complications increase
ven further during pandemic seasons [10,11].
Based on the potential for maternal morbidity and mortal-
ty associated with inﬂuenza during pregnancy, the CDC and
he American College of Obstetrics & Gynecology (ACOG) recom-
end inactivated inﬂuenza vaccine (IIV) for all women who  will
e pregnant during inﬂuenza season [12]. Initial recommenda-
ions for IIV administration during pregnancy made in 1997 were
xtrapolated from the documented efﬁcacy and safety of IIV in non-
regnant adults. Until the 2009 pandemic, there were only a few
mall-scale studies on the safety and immunogenicity of mater-
al inﬂuenza vaccination. In a randomized trial of 340 pregnant
omen in Bangladesh, Zaman et al. demonstrated a 36% reduction
n laboratory-conﬁrmed inﬂuenza among women who  received IIV
uring the third trimester compared to women who  received pneu-
ococcal vaccine [2]. While this study was potentially limited by
he lack of a placebo control group, Madhi et al. recently com-
leted a randomized trial of IIV vs. placebo in ∼2000 pregnant
omen in South Africa [13]. With inﬂuenza attack rates of 3.6% vs.
.8% among HIV uninfected placebo and IIV groups respectively,
IV vaccine efﬁcacy in this pregnant population was  50.4% (95%
I 14.5–71.2). For women with HIV infection, vaccine efﬁcacy was
7.7% (95% CI 0.2–82.1) with attack rates of 17% vs. 7% for placebo
nd IIV groups, respectively. Black et al. were unable to demonstrate
accine effectiveness against hospital admissions and physician
utpatient visits due to respiratory illness among pregnant women
ared for in a health system level analysis over ﬁve consecutive
on-pandemic seasons [14]. The lack of demonstrated effectiveness
ay  be due to the use of respiratory illness rather than laboratory
onﬁrmed inﬂuenza and that hospitalizations among the entire
opulation of pregnant women were uncommon, regardless of
accination status. However, a population-based study of 117,347
orwegian women who were pregnant during the 2009–2010 pan-
emic revealed a 70% reduction in clinical diagnosis of inﬂuenza,
uggesting that vaccine efﬁcacy during a novel pandemic season
ay  offer even greater maternal beneﬁt than seasonal vaccination
15].
Successful public health promotion by the CDC and ACOG led
o inﬂuenza vaccine coverage exceeding 50% for the ﬁrst time
n 2012–2013 [16]. Studies assessing vaccine acceptance have
learly identiﬁed a lack of knowledge of recommendations, lack
f obstetric provider recommendation, and lack or misunderstand-
ng of safety data during pregnancy as the key factors inﬂuencing
nﬂuenza vaccine uptake during pregnancy [17,18]. Thus, con-
inued research on inﬂuenza vaccination during pregnancy and
ducation of obstetric providers and pregnant women is warranted.
ith approximately 4 million births in the US annually, maternal
nﬂuenza immunization has great potential to improve maternal
ealth during pregnancy and the immediate postpartum period
hen the risks of inﬂuenza are greatest.2.2. Tetanus, diphtheria, and pertussis
Childhood vaccination combined with decennial booster and
exposure-related dosing against tetanus and diphtheria has led to
the near eradication of both diseases in the US. Pertussis or “whoop-
ing cough”, however, has been on the rise for the last two to three
decades following a long period of active disease control and pre-
vention. Although the incidence of pertussis has increased across
the entire population, disease-related morbidity and mortality pri-
marily affects infants [19]. Infants are most commonly exposed to
pertussis through close contact, with 47–60% of cases due to expo-
sure from infected parents [20]. Furthermore, adults with pertussis
are often unaware of their diagnosis, given that many adults are
either asymptomatic or have symptoms of a common cold.
Vaccination efforts to reduce the incidence of pertussis among
young infants have previously focused on cocooning, or strate-
gies to immunize close contacts of young infants against pertussis.
The initial strategy including immediate postpartum maternal
vaccination combined with antenatal vaccination among previ-
ously non-vaccinated pregnant women  failed to affect the ongoing
pertussis outbreaks. In October 2012, the CDC changed its rec-
ommendation on vaccination during pregnancy, now advising
obstetric providers to administer Tdap during each pregnancy,
regardless of prior Tdap receipt [4]. This strategy is based on
the concept of passive immunization in which maternally-derived
vaccine-induced antibodies cross the placenta into the fetal cir-
culation. Passive immunization can protect young infants during
the ﬁrst few months of life when they are most vulnerable to per-
tussis and prior to establishing immunity from their own primary
vaccination series [20,21].
While it is imperative that we  continue efforts to reduce the
incidence of infant pertussis, many questions remain regarding
the potential beneﬁts and/or risks of Tdap administration during
pregnancy, including the potential effect of repeated close-interval
dosing among women having more than one pregnancy in a rel-
atively short period of time, e.g. 1–3 years, and whether repeated
doses of Tdap actually continues to boost pertussis antibody levels
in pregnant women. Although relatively small with 48 pregnant
and 32 non-pregnant, Tdap naïve women, Munoz et al. demon-
strated that Tdap administration during pregnancy is immunogenic
and safe [22]. However, the overall lack of data on the potential
maternal beneﬁt of Tdap vaccination, i.e., to prevent pertussis in
pregnant women  themselves, as well as the lack of both immuno-
genicity and safety data following repeated Tdap administration,
represents a signiﬁcant knowledge gap. Ongoing larger-scale stud-
ies of Tdap during pregnancy will provide much needed data in the
near future [23,24].
3. Vaccines recommended for all pregnant women  with
risk factors3.1. Pneumococcal disease
Pneumococcal disease, caused by the Gram-positive Strep-
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orbidity and mortality resulting from pneumonia, bacteremia,
nd meningitis [25]. Pneumococcal pneumonia, the most common
anifestation, affects ∼900,000 Americans and results in 400,000
ospitalizations and 5–7% mortality each year. Less common pre-
entations include bacteremia and meningitis, which affect about
2,000 and 3000 individuals each year, respectively, with 10–15%
ortality. Although the incidence of pneumonia during pregnancy
s fairly low, the disease course is similar to that of inﬂuenza, likely
ttributable to the same pregnancy-associated physiologic respira-
ory changes and alterations in cell-mediated immunity, resulting
n higher rates of hospitalization, acute respiratory distress syn-
rome (ARDS), cardiorespiratory failure, and death [26]. Obstetric
omplications include fetal distress, preterm birth, and low birth-
eight [26].
Current CDC guidelines recommend the 23-serotype polysac-
haride vaccine (PPSV23) for children and adults with chronic
edical conditions and other risk factors including chronic heart
r lung disease (asthma, diabetes, cigarette smoking), alco-
olism, chronic liver disease, cerebrospinal ﬂuid leaks, cochlear
mplants, congenital or acquired immunodeﬁciencies, diseases
equiring immunosuppressant therapy, sickle cell disease and
ther hemoglobinopathies, and functional or anatomic asplenia
27]. In addition, the 13-serotype pneumococcal conjugate vaccine
PCV13) is recommended for all children and additional high risk
dult subpopulations [28]. While currently available data do not
upport the need for widespread use of PCV13 or PPSV23 during
regnancy [29], a systematic review of observational studies and a
andomized trial of PPSV23 given during pregnancy demonstrated
o maternal or fetal safety concerns [22,30]. Furthermore, maternal
PSV23 vaccination provides protective antibody levels for at least
ne year following delivery and higher neonatal antibody levels. A
ecent Cochrane review found insufﬁcient evidence to suggest that
aternal vaccination could reduce infant pneumococcal infection
ia passive immunization [31]. Nevertheless, in accordance with
DC guidelines for adult immunization, PPSV23 should be given to
regnant women for their own beneﬁt with additional risk factors
s described above.
.2. Meningococcal disease
Neisseria meningitidis causes rare, but often deadly, meningi-
is and sepsis in about 1000 people in the US each year [32].
lthough susceptible to antibiotics, meningococcal disease carries
 mortality rate of 10–15% and a 20% rate of severe morbidity
mong survivors including limb amputations, strokes, and neu-
ocognitive abnormalities. In 2005, the tetravalent meningococcal
onjugate vaccine (MCV4) was included in the US adolescent vacci-
ation schedule, replacing the tetravalent polysaccharide vaccine
MPSV4) based on a longer duration of vaccine-induced immu-
ity with MCV4. Similar to PPSV23 and PCV13, there are several
dult subgroups who are at high risk for meningococcal infection:
hose in close living conditions such as dormitories or military bar-
acks, those with complement deﬁciencies, functional or anatomic
splenia, those residing in hyperendemic areas, and laboratory staff
orking with N. meningitidis.
Previously unvaccinated pregnant women with risk factors
or meningococcal disease should be vaccinated. Although MCV4
nd MPSV4 are both inactivated products which should not
arry any maternal or fetal risk, available data on meningococ-
al vaccination in pregnancy involves MPSV4 rather than MCV4.
 systematic review of maternal MPSV4 demonstrated no con-
ern for maternal or fetal complications [30]. O’Dempsey et al.
emonstrated an adequate maternal antibody response follow-
ng MPSV4 vaccination in the third trimester [33]. Given the
ack of available safety data on MCV4, MPSV4 is recommendede 33 (2015) 6436–6440
for use during pregnancy based on risk factors described
above [29].
3.3. Hepatitis A
Although generally self-limiting, hepatitis A virus (HAV) causes
fever, vomiting, and jaundice due to acute liver infection. As HAV
is transmitted via fecal-oral contamination from close contact with
infected individuals or contaminated food or drinks, the general
public is at risk for HAV infection [34]. Widespread vaccination
against HAV in the US began in 1999 and has led to a signiﬁ-
cant drop in documented cases of HAV in the US [35]. Although
HAV vaccination is currently included in the CDC recommended
childhood immunization schedule, vaccination against HAV is also
recommended for people with high risk for HAV exposure: those
traveling to endemic areas, men  who have sex with men, those
in close contact with individuals with HAV infection or receipt
of clotting-factor concentrates, and laboratory or healthcare staff
working with biological specimens. Consistent with CDC guide-
lines, pregnant women  with identiﬁable risk factors should receive
HAV vaccine [34]. Although the data on HAV vaccine safety during
pregnancy is lacking, the current inactivated HAV vaccine does not
contain live virus components and is exceedingly unlikely to carry
any risk of maternal or fetal harm.
3.4. Hepatitis B
Associated with acute liver inﬂammation, vomiting, and jaun-
dice, hepatitis B virus (HBV) can either be self-limiting or lead to
a chronic carrier state with long-term morbidity (cirrhosis, liver
cancer, liver failure) and mortality. Individuals with close contact
with an HBV-infected individual’s blood and bodily ﬂuids are at risk
for disease. The three-dose recombinant DNA HBV vaccine series
provides indeﬁnite immunity in most individuals (>90%) and is
currently initiated at birth as part of the CDC recommended child-
hood immunization schedule [36]. Vaccination against HBV has
been proven to be effective given the greater than 60% reduction in
reported cases of HBV over the last 15–20 years [35].
Much of the attention on HBV during pregnancy focuses on
the risk of perinatal transmission following primary or chronic
maternal infection, particularly given the high risk of chronic dis-
ease development following perinatal acquisition. As part of that
focus, pregnant women are routinely screened for HBV via surface
antigen (HBsAg) testing followed by neonatal treatment with HB
immunoglobulin (HBIg) prophylaxis and HBV vaccination during
the ﬁrst hours of life for infants born to HBV infected mothers [37].
However, unvaccinated pregnant women  with risk factors for HBV
acquisition should be counseled on the extremely high effective-
ness of HBV vaccination to prevent maternal and subsequent fetal
infection. Individuals at high risk of HBV acquisition include those
with one or more sexual partner in the past six months, household
or sexual contact with an HBV-infected individual, or intravenous
drug use [36]. Although extensive safety data are limited, HBV
vaccination during pregnancy has not been associated with any
maternal or fetal complications [30]. Therefore, the three-dose HBV
vaccine series should be initiated for previously unvaccinated or
incompletely vaccinated pregnant women with risk factors for HBV
infection.
4. Novel vaccines aimed at reducing infant infection
through maternal immunization
Similar to the recommendation for Tdap to be administered dur-
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 streptococcus (GBS) and respiratory syncytial virus (RSV) during
arly infancy are in development.
.1. Group B Streptococcus
GBS is leading cause of invasive infection within the ﬁrst three
onths of life, resulting most commonly in sepsis and meningitis
38]. Intrapartum antibiotic prophylaxis has signiﬁcantly reduced
he incidence of early-onset neonatal GBS (within the ﬁrst seven
ays of life) in the US. However, there has been no change in
he rates of late-onset GBS disease (from one week to three
onths of age), which occurs in 0.29–0.47 per 1000 live births and
an be equally devastating. Furthermore, strategies of screening
lus intrapartum antibiotic prophylaxis are often impractical in
ow-resources settings. Based on available evidence of neonatal
rotection against GBS disease in the setting of passive immu-
ity [39], a vaccine against GBS could have a signiﬁcant impact on
reventing both early- and late-onset disease.
Albeit the primary objective of a GBS vaccine will be to
educe infant infection, it is highly plausible that a GBS vaccine
ould have signiﬁcant beneﬁts for maternal health and ultimately
verall pregnancy outcomes. In addition to asymptomatic cervico-
aginal colonization, GBS causes numerous maternal infections
40]. Although most GBS urinary tract infections are asymptomatic,
BS causes about 10% of acute pyelonephritis in pregnancy, which
s highly concerning given the association of pyelonephritis with
dverse pregnancy outcomes (preterm birth, low birthweight, fetal
emise) [41]. Intra-amniotic infection (IAI) is caused by the ascend-
ng spread of vaginal ﬂora, with GBS detected in the amniotic ﬂuid
f 15% of cases. Maternal consequences of IAI include serious mater-
al pelvic infections, sepsis, and postpartum hemorrhage. Maternal
acteremia occurs in 2–6% of IAI cases overall and in up to 35%
f cases with conﬁrmed GBS-related puerperal infection – IAI and
ostpartum endometritis. While septic shock is rare, GBS sepsis
ollows bacteremia in 5–25% of cases [42].
A trivalent conjugated GBS vaccine is being evaluated in phase II
nd III studies in pregnant women, with a focus on third trimester
dministration to theoretically maximize passive immunity at the
eight of antibody transfer rates [6,43]. Although the morbidity
f maternal GBS infection is certainly less than that in the young
nfant, maternal disease occurs more frequently and endangers
oth mother and infant. Evaluation of the efﬁcacy of the vaccine
o prevent maternal GBS infection as well as optimal timing of
dministration to beneﬁt both mother and infant will be crucial.
.2. Respiratory syncytial virus
In the ﬁrst year of life, RSV is the leading source of bronchioli-
is and pneumonia, and frequently results in hospitalization and
ecurrent wheezing or asthma. Sixty percent of infants in the US
ill suffer from the infection during their ﬁrst winter–spring RSV
eason [44]. While RSV has evaded effective vaccine development
n the past and even been associated with enhanced childhood dis-
ase in the setting of formalin-inactivation [45], numerous vaccine
andidates are in development with target populations ranging
rom neonates to the elderly. A recombinant RSV vaccine is cur-
ently under evaluation in a phase II trial of pregnant women with
he goal of providing neonatal protection [5]. The effectiveness of
assive immunization to prevent RSV infection in young infants
s supported by higher RSV cord blood antibody titers resulting in
ower rates of serologic infant infection [46].
There is a paucity of data available on the incidence and impact
f maternal RSV infection during pregnancy. A recent study by
alsey et al. identiﬁed the signiﬁcant contribution of RSV to acute
espiratory infection outside of childhood, with a 4–10% incidence
mong high-risk and elderly adults annually. Among the 85% of
[e 33 (2015) 6436–6440 6439
symptomatic individuals, 16% required hospitalization with 4%
mortality and disease burden estimates similar to inﬂuenza [47].
We recently published a series of three cases of RSV infection during
pregnancy, two  of which required maternal mechanical ventila-
tion and critical care due to severe respiratory compromise [48].
Given the similarities with inﬂuenza, it is very possible that the
incidence and associated complications of maternal RSV infection
have been underestimated. If this is in fact the case, the potential
for a combined maternal and infant beneﬁt of an efﬁcacious RSV
vaccine could be great.
5. Summary
Pregnant women have unique and heightened susceptibilities
to greater morbidity and mortality from a variety of bacterial
and viral vaccine-preventable diseases. Currently signiﬁcant atten-
tion is focused on developing vaccines for use during pregnancy
with the primary goal of preventing infections in young infants.
While this approach holds tremendous potential for sizable disease
prevention in infants, pregnant women  also have signiﬁcant oppor-
tunity for disease prevention from both currently recommended
and future vaccines. Maternal-child health can and will continue to
be improved with ongoing efforts to prevent numerous infectious
diseases in both mothers and infants.
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